© 2015

Pharmaceutical Prices in the 21st Century

  • Zaheer-Ud-Din Babar

Table of contents

  1. Front Matter
    Pages i-x
  2. Agnes Isabelle Vitry, Loc Thai, Elizabeth E. Roughead
    Pages 1-23
  3. Joel Lexchin
    Pages 25-41
  4. Heba Wanis
    Pages 59-78
  5. Eskinder Eshetu Ali, Anwarul-Hassan Gilani, Teferi Gedif
    Pages 79-91
  6. Katja M. Hakkarainen, Akseli Kivioja, Leena K. Saastamoinen
    Pages 93-112
  7. Sudip Chaudhuri
    Pages 113-130
  8. Claudio Jommi, Paola Minghetti
    Pages 131-150
  9. Iyn-Hyang Lee, Karen Bloor
    Pages 151-169
  10. Mohamed Azmi Hassali, Ching Siang Tan, Zhi Yen Wong, Fahad Saleem, Alian A. Alrasheedy
    Pages 171-188
  11. Rajan Ragupathy, Kate Kilpatrick, Zaheer-Ud-Din Babar
    Pages 189-207
  12. Helle Håkonsen, Karolina Andersson Sundell
    Pages 209-227
  13. Mohamed Izham Mohamed Ibrahim
    Pages 229-249
  14. Andy Gray, Fatima Suleman
    Pages 251-265
  15. Albert I. Wertheimer, Ming-Yi Huang
    Pages 309-319
  16. Tuan Anh Nguyen, Elizabeth E. Roughead
    Pages 321-342
  17. Sabine Vogler, Jaana E. Martikainen
    Pages 343-370

About this book


The book is an essential, comprehensive text onglobal drug pricing and covers a range of pharmaceutical pricing issues. It has twenty-two chapters in total;nineteenof which are case studieson an array of high, middle, and low income countries. The final three chaptersdiscussvalue-based pricing, innovation, prices and the pharmaceutical industry and the link betweenpharmaceutical policy and pricing. As the pharmaceutical market continues to expand, a number of pharmaceutical pricing strategies have been employed to control drug expenditures. The book explores this phenomenon further and willserve a valuable resource for policy makers, funders, social insurance institutions and drug companies.

 About the author

Zaheer-Ud-Din Babar, PhD is the Head of Pharmacy Practice at the School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, New Zealand. A pharmacist by training and a PhD in pharmaceutical policy, Dr Babar is a recipient of the prestigious “Research Excellence Award” from the University of Auckland. His research program covers areas related to pharmaceutical policy and practice, encompassing access to and affordability of medicines, issues related to medicine pricing and pharmacoeconomics. Dr Babar has delivered invited lectures at Boston University School of Public Health, Harvard Medical School, the Austrian Health Institute and the Universities of Reading and Kingston. He has also acted as a consultant for the World Health Organization, Health Action International, the International Union against Tuberculosis and Lung Disease, the International Pharmaceutical Federation (FIP) and the Pharmaceutical Management Agency of New Zealand in the area of medicines pricing and policies. Dr Babar is the Editor in Chief of the Journal of Pharmaceutical Policy and Practice, and can be reached at


Drug expenditure Global pharmaceutical pricing policies Pharmaceutical market Prices of vaccines Pricing strategies and policies

Editors and affiliations

  • Zaheer-Ud-Din Babar
    • 1
  1. 1.Faculty of Medical and Health SciencesUniversity of AucklandAucklandNew Zealand

Bibliographic information

  • Book Title Pharmaceutical Prices in the 21st Century
  • Editors Zaheer-Ud-Din Babar
  • DOI
  • Copyright Information Springer International Publishing Switzerland 2015
  • Publisher Name Adis, Cham
  • eBook Packages Business and Economics Economics and Finance (R0)
  • Hardcover ISBN 978-3-319-12168-0
  • Softcover ISBN 978-3-319-35009-7
  • eBook ISBN 978-3-319-12169-7
  • Edition Number 1
  • Number of Pages X, 411
  • Number of Illustrations 3 b/w illustrations, 34 illustrations in colour
  • Topics Health Economics
  • Buy this book on publisher's site
Industry Sectors
Finance, Business & Banking


“This book is a collection of national case studies about pharmaceutical pricing policy. … this book offers a wealth of examples to consider, especially for low- and middle-income countries that are in the process of changing or establishing health insurance programs. Having a consolidated reference source, such as this book, for academics interested in the field of policy analysis will obviously be very useful.” (Suzanne Rose Hill, PharmacoEconomics, Vol. 34 (3), March, 2016)